According to the Public Relations Department of the Actover Pharmaceutical Group, the 20th International Congress of the Iranian Society of Gynecologists and Obstetricians was held with the aim of enhancing the knowledge and expertise of doctors in the field of gynecology and obstetrics.

At this congress, the latest scientific advancements in gynecology and obstetrics were shared with specialists. AtiPharmed’s scientific symposium titled “The Role of Estrogen in ART and HRT” was one of the numerous panels held at this specialized congress. During this symposium, Dr. Robabeh Taheri Panah, professor at Shahid Beheshti University, presented scientific information on estrogen therapy. Following this, Dr. Shahrzad Dehnad, the medical advisor for AtiPharmed, introduced Gynati and Prequin, the company’s newest medications.

AtiPharmed Pharmaceutical Factory: A Pioneer in High-Quality Hormonal Drug Production

AtiPharmed, a subsidiary of the Actover Pharmaceutical Group, was established with the goal of producing hormonal drugs utilizing the latest global technologies. This factory is recognized as the first manufacturer of hormonal drugs with GMP certification in Iran.

The new products from this factory include two drugs used in hormone therapy after menopause. The drug “Gynati” is a vaginal tablet containing 10 micrograms of estradiol hemihydrate, and the drug ” Prequin ” is an oral tablet containing conjugated estrogens, produced in three doses: 0.3, 0.625, and 1.25 milligrams. The 0.3 milligram dose of this drug is being produced in Iran for the first time by AtiPharmed.